NRX Pharmaceuticals (NRXP) Assets Average (2018 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Assets Average of $12.4 million for Q1 2026, up 121.15% year-over-year from $5.6 million in Q1 2025, and down 11.07% quarter-over-quarter from $14.0 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Assets Average (2018 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Assets Average for 9 consecutive years, with $12.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 121.15% year-over-year to $12.4 million; the TTM figure through Mar 2026 stood at $12.4 million (up 121.15% YoY), while the FY2025 annual figure was $8.3 million, up 51.44% from the prior year.
- Assets Average declined to $12.4 million in Q1 2026 per NRXP's latest filing, from $14.0 million in the prior quarter.
- Across five years, Assets Average topped out at $38.2 million in Q1 2022 and bottomed at $4.1 million in Q4 2024.
- Historically, Assets Average has averaged $15.8 million across 5 years, with a median of $12.4 million in 2026.
- Annual changes were most pronounced in 2022 — Assets Average soared 751.05% — and 2024, when it plunged 78.23%.
- NRX Pharmaceuticals' Assets Average stood at $25.3 million in 2022, then sank by 59.67% to $10.2 million in 2023, then plunged by 60.28% to $4.1 million in 2024, then jumped by 244.53% to $14.0 million in 2025, then slipped by 11.07% to $12.4 million in 2026.
- Business Quant data shows NRXP's Assets Average at $12.4 million in Q1 2026, $14.0 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 19.82 Bn |
| 10 | NRX Pharmaceuticals | 132.83 Mn | 106.13 Mn | 426,000.00 | 23.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.43 Mn |
| Dec 31, 2025 | 13.98 Mn |
| Sep 30, 2025 | 9.92 Mn |
| Jun 30, 2025 | 6.21 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 5.55 Mn |
| Dec 31, 2023 | 10.21 Mn |
| Sep 30, 2023 | 16.46 Mn |
| Jun 30, 2023 | 20.79 Mn |
| Mar 31, 2023 | 23.80 Mn |
| Dec 31, 2022 | 25.32 Mn |
| Sep 30, 2022 | 28.63 Mn |
| Jun 30, 2022 | 38.02 Mn |
| Mar 31, 2022 | 38.17 Mn |
| Dec 31, 2021 | 38.99 Mn |
| Sep 30, 2021 | 31.90 Mn |
| Jun 30, 2021 | 12.29 Mn |